StockMacro
Menu

United Therapeutics

$554.73 -4.1% in 6 monthsMarket cap $23.6B

UTHR on XNAS, Health Care, United Therapeutics Corp, job postings

Measures activity, not value. Not investment advice.

Insiders sold $348.3M in 90 days with no purchases, while the stock rose 17% in a year.

  • BadNet income fell 3.2% to $1.2B over the last 12 months

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Industry
Pharmaceutical preparations (Health Care)
Employees
1,400
Website
unither.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 24 Feb 2027 (an estimate: a year ago it reported on 25 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $832.5M, net income $258.6M.
Quarter to 31 Dec 2021: revenue $415.2M, net income –Quarter to 31 Mar 2022: revenue $461.9M, net income $239.9MQuarter to 31 Mar 2022: revenue $461.9M, net income $239.9MQuarter to 30 Jun 2022: revenue $466.9M, net income $116.0MQuarter to 30 Jun 2022: revenue $466.9M, net income $116.0MQuarter to 30 Sep 2022: revenue $516.0M, net income $239.3MQuarter to 30 Sep 2022: revenue $516.0M, net income $239.3MQuarter to 31 Dec 2022: revenue $491.5M, net income –Quarter to 31 Mar 2023: revenue $506.9M, net income $240.9MQuarter to 31 Mar 2023: revenue $506.9M, net income $240.9MQuarter to 30 Jun 2023: revenue $596.5M, net income $259.2MQuarter to 30 Jun 2023: revenue $596.5M, net income $259.2MQuarter to 30 Sep 2023: revenue $609.4M, net income $267.6MQuarter to 30 Sep 2023: revenue $609.4M, net income $267.6MQuarter to 31 Dec 2023: revenue $614.7M, net income $217.1MQuarter to 31 Dec 2023: revenue $614.7M, net income $217.1MQuarter to 31 Mar 2024: revenue $677.7M, net income $306.6MQuarter to 31 Mar 2024: revenue $677.7M, net income $306.6MQuarter to 30 Jun 2024: revenue $714.9M, net income $278.1MQuarter to 30 Jun 2024: revenue $714.9M, net income $278.1MQuarter to 30 Sep 2024: revenue $748.9M, net income $309.1MQuarter to 30 Sep 2024: revenue $748.9M, net income $309.1MQuarter to 31 Dec 2024: revenue $735.9M, net income $301.3MQuarter to 31 Dec 2024: revenue $735.9M, net income $301.3MQuarter to 31 Mar 2025: revenue $794.4M, net income $322.2MQuarter to 31 Mar 2025: revenue $794.4M, net income $322.2MQuarter to 30 Jun 2025: revenue $798.6M, net income $309.5MQuarter to 30 Jun 2025: revenue $798.6M, net income $309.5MQuarter to 30 Sep 2025: revenue $799.5M, net income $338.7MQuarter to 30 Sep 2025: revenue $799.5M, net income $338.7MQuarter to 31 Dec 2025: revenue $790.2M, net income $364.3MQuarter to 31 Dec 2025: revenue $790.2M, net income $364.3MQuarter to 31 Mar 2026: revenue $781.5M, net income $274.9MQuarter to 31 Mar 2026: revenue $781.5M, net income $274.9MQuarter to 30 Jun 2026: revenue $783.3M, net income $333.0MQuarter to 30 Jun 2026: revenue $783.3M, net income $333.0MQuarter to 30 Sep 2026: revenue $832.5M, net income $258.6MQuarter to 30 Sep 2026: revenue $832.5M, net income $258.6M
31 Dec 2021RevenueNet incometallest bar $832.5M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$832.5M$258.6M
30 Jun 2026$783.3M$333.0M
31 Mar 2026$781.5M$274.9M
31 Dec 2025$790.2M$364.3M
30 Sep 2025$799.5M$338.7M
30 Jun 2025$798.6M$309.5M
31 Mar 2025$794.4M$322.2M
31 Dec 2024$735.9M$301.3M
30 Sep 2024$748.9M$309.1M
30 Jun 2024$714.9M$278.1M
31 Mar 2024$677.7M$306.6M
31 Dec 2023$614.7M$217.1M
30 Sep 2023$609.4M$267.6M
30 Jun 2023$596.5M$259.2M
31 Mar 2023$506.9M$240.9M
31 Dec 2022$491.5M–
30 Sep 2022$516.0M$239.3M
30 Jun 2022$466.9M$116.0M
31 Mar 2022$461.9M$239.9M
31 Dec 2021$415.2M–
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $3.2B $3.1B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +1.9% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $1.2B $1.3B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $26.49 $26.41
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 86.3% 88.6% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 41.4% 47.7% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 38.6% 40.7% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 19.1% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $867.2M $1.1B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $2.1B $2.8B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $147.36
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 19.2 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 7.4 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.8 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
United TherapeuticsUTHR (this company) $23.6B19.27.4+1.9%38.6%
ViatrisVTRS $22.5Bloss1.5+4.3%-4.1%
Roivant SciencesROIV $28.0Bloss682–-838%
Alnylam PharmaceuticalsALNY $19.3B7.3–––
Royalty PharmaRPRX $30.5B45.411.6+11%25.7%
InsmedINSM $31.0Bloss20.4+240%-39.9%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$348.3M

bought $0, sold $348.3M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-2.2%

839 13F filers vs 858

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

42.7M shares held by 13F filers (30 Sep 2026) of 42.6M outstanding (28 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

4.3%

1.8M shares sold short (30 Oct 2026) of 42.6M outstanding (28 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.5

1.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-25%

2.5M shares sold short in the report before, 1.8M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

60%

60% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 54%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

+50%

15 vs 10 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+4.1%

$832.5M vs $799.5M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-14%

$180.7M vs $210.5M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$1.3M

the 12 months before: $610K

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$300K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

39

39 articles in the last 7 days; its usual week has 5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

7.8×

39 articles in the last 7 days; its usual week has 5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 3.6M, 1.6× a year earlier

Price $554.73 on 20 Nov 2026, +17% over 12 months (12-month range $464.93 to $608.49)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $1.4B in the last 12 months (the 12 months before: -$422.8M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 15 published in the last 12 months, +50% on the 12 months before.
Revenue per quarter. Revenue $832.5M in the latest quarter, +4.1% on a year earlier.
Capital spending per quarter. Capital spending $180.7M in the latest quarter, -14% on a year earlier.
Institutional holders (13F filers). 839 13F filers reported holding it in the latest 13F quarter, +26% on a year earlier.
Federal obligations. Federal obligations: $752K published in the last 12 months, -7.8% on the 12 months before.
Lobbying spend. Lobbying spend: $300K published in the last 12 months, +1400% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
13 Oct 2026Sharp changeShort interest spike: short interest spike, 3.6M vs usual 2.1M (2026-09-30); 1.6x the same period a year earlier
23 Jul 20268-K and other filingsDirector or officer change
29 Jun 20268-K and other filingsDirector or officer change
29 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Apr 2026Sharp changeLobbying on a new issue: lobbying on a new issue: HCR (2026-03-31)
14 Apr 2026Sharp changeShort interest spike: short interest spike, 2.8M vs usual 1.8M (2026-03-31); 1.7x the same period a year earlier
31 Mar 2026Sharp changeShort interest spike: short interest spike, 2.8M vs usual 1.8M (2026-03-13); 1.6x the same period a year earlier
26 Feb 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 172.9M vs usual 75.7M (2025-12-31); 2.0x the same period a year earlier
22 Jan 20268-K and other filingsDirector or officer change
22 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Jan 2026Sharp changeLobbying on a new issue: lobbying on a new issue: POS (2025-12-31)
30 Oct 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 210.5M vs usual 70.3M (2025-09-30); 2.8x the same period a year earlier
16 Oct 2025Lobbying filingnew lobbying registration (TIBER CREEK GROUP)
27 Jun 20258-K and other filingsDirector or officer change
27 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Apr 20258-K and other filingsA major agreement ended
17 Sep 2024Sharp changeShort interest spike: short interest spike, 4.1M vs usual 1.2M (2024-08-30); 3.7x the same period a year earlier
27 Aug 2024Sharp changeShort interest spike: short interest spike, 4.1M vs usual 1.2M (2024-08-15); 2.2x the same period a year earlier
13 Aug 2024Sharp changeShort interest spike: short interest spike, 4.1M vs usual 1.2M (2024-07-31); 4.2x the same period a year earlier
30 Jul 2024Sharp changeShort interest spike: short interest spike, 4.2M vs usual 1.2M (2024-07-15); 4.2x the same period a year earlier
16 Jul 2024Sharp changeShort interest spike: short interest spike, 4.4M vs usual 1.1M (2024-06-28); 4.1x the same period a year earlier
2 Jul 2024Sharp changeShort interest spike: short interest spike, 4.4M vs usual 1.1M (2024-06-14); 3.8x the same period a year earlier
27 Jun 20248-K and other filingsDirector or officer change
27 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Jun 2024Sharp changeShort interest spike: short interest spike, 3.9M vs usual 1.1M (2024-05-31); 3.7x the same period a year earlier
28 May 2024Sharp changeShort interest spike: short interest spike, 3.8M vs usual 1.1M (2024-05-15); 2.8x the same period a year earlier
14 May 2024Sharp changeShort interest spike: short interest spike, 3.9M vs usual 1.1M (2024-04-30); 2.6x the same period a year earlier
30 Apr 2024Sharp changeShort interest spike: short interest spike, 4.3M vs usual 1.1M (2024-04-15); 3.1x the same period a year earlier
16 Apr 2024Sharp changeShort interest spike: short interest spike, 4.9M vs usual 1.1M (2024-03-28); 3.4x the same period a year earlier
2 Apr 2024Sharp changeShort interest spike: short interest spike, 1.9M vs usual 1.1M (2024-03-15); 1.4x the same period a year earlier
29 Aug 2023Sharp changeShort interest spike: short interest spike, 1.9M vs usual 1.3M (2023-08-15); 1.8x the same period a year earlier
28 Jun 20238-K and other filingsDirector or officer change
28 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Nov 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 68.8M vs usual 16.1M (2022-09-30); 3.0x the same period a year earlier
28 Jun 20228-K and other filingsDirector or officer change
28 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Apr 20228-K and other filingsA major agreement ended
1 Mar 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 70.6M vs usual 16.1M (2021-12-31); 5.7x the same period a year earlier
Insider net buying (open market)
Month from 1 Nov 2021: -$1.2M published
Month from 1 Dec 2021: -$4.9M published
Month from 1 Jan 2022: -$2.4M published
Month from 1 Feb 2022: -$2.4M published
Month from 1 Mar 2022: -$2.1M published
Month from 1 Apr 2022: -$2.2M published
Month from 1 May 2022: -$10.1M published
Month from 1 Jun 2022: -$8.4M published
Month from 1 Jul 2022: -$3.3M published
Month from 1 Aug 2022: -$1.8M published
Month from 1 Sep 2022: -$2.3M published
Month from 1 Oct 2022: -$3.0M published
Month from 1 Nov 2022: -$45.1M published
Month from 1 Dec 2022: -$50.8M published
Month from 1 Jan 2023: -$47.9M published
Month from 1 Feb 2023: -$39.9M published
Month from 1 Mar 2023: -$45.2M published
Month from 1 Apr 2023: -$40.7M published
Month from 1 May 2023: -$8.2M published
Month from 1 Jun 2023: -$2.6M published
Month from 1 Jul 2023: -$1.9M published
Month from 1 Aug 2023: -$2.8M published
Month from 1 Sep 2023: -$2.8M published
Month from 1 Oct 2023: -$2.7M published
Month from 1 Nov 2023: -$2.7M published
Month from 1 Dec 2023: -$3.8M published
Month from 1 Jan 2024: -$2.7M published
Month from 1 Feb 2024: -$3.0M published
Month from 1 Mar 2024: -$70.3M published
Month from 1 Apr 2024: -$37.0M published
Month from 1 May 2024: -$37.3M published
Month from 1 Jun 2024: -$26.0M published
Month from 1 Jul 2024: -$23.5M published
Month from 1 Aug 2024: -$39.4M published
Month from 1 Sep 2024: -$12.7M published
Month from 1 Oct 2024: -$13.9M published
Month from 1 Nov 2024: -$39.5M published
Month from 1 Dec 2024: -$27.4M published
Month from 1 Jan 2025: -$20.0M published
Month from 1 Feb 2025: -$14.3M published
Month from 1 Mar 2025: -$11.6M published
Month from 1 Apr 2025: -$9.3M published
Month from 1 May 2025: -$10.8M published
Month from 1 Jun 2025: -$15.1M published
Month from 1 Jul 2025: -$6.6M published
Month from 1 Aug 2025: -$6.7M published
Month from 1 Sep 2025: -$72.1M published
Month from 1 Oct 2025: -$101.2M published
Month from 1 Nov 2025: -$127.6M published
Month from 1 Dec 2025: -$124.8M published
Month from 1 Jan 2026: -$51.8M published
Month from 1 Feb 2026: -$47.4M published
Month from 1 Mar 2026: -$119.7M published
Month from 1 Apr 2026: -$183.8M published
Month from 1 May 2026: -$173.6M published
Month from 1 Jun 2026: -$150.4M published
Month from 1 Jul 2026: -$121.6M published
Month from 1 Aug 2026: -$112.0M published
Month from 1 Sep 2026: -$107.3M published
Month from 1 Oct 2026: -$130.2M published
Month from 1 Nov 2026: -$86.2M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 2 published
Quarter from 1 Apr 2022: 1 published
Quarter from 1 Jul 2022: 1 published
Quarter from 1 Oct 2022: 1 published
Quarter from 1 Jan 2023: 1 published
Quarter from 1 Jul 2023: 4 published
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Jan 2024: 5 published
Quarter from 1 Apr 2024: 3 published
Quarter from 1 Jul 2024: 1 published
Quarter from 1 Oct 2024: 3 published
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Apr 2025: 1 published
Quarter from 1 Jul 2025: 7 published
Quarter from 1 Oct 2025: 1 published
Quarter from 1 Apr 2026: 2 published
Quarter from 1 Jul 2026: 9 published
Quarter from 1 Oct 2026: 4 published
Revenue per quarter
Quarter ended 31 Dec 2021: $415.2M, +7.9% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $461.9M, +22% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $466.9M, +4.6% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $516.0M, +16% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $491.5M, +18% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $506.9M, +9.7% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $596.5M, +28% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $609.4M, +18% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $614.7M, +25% on a year earlier; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $677.7M, +34% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $714.9M, +20% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $748.9M, +23% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $735.9M, +20% on a year earlier; public on 27 Feb 2025
Quarter ended 31 Mar 2025: $794.4M, +17% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $798.6M, +12% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $799.5M, +6.8% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $790.2M, +7.4% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $781.5M, -1.6% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $783.3M, -1.9% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $832.5M, +4.1% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $70.6M, +474% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $13.5M, +27% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $17.0M, +4.3% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $68.8M, +195% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $39.5M, -44% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $41.3M, +206% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $44.7M, +163% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $65.7M, -4.5% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $78.7M, +99% on a year earlier; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $38.2M, -7.5% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $45.1M, +0.9% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $76.5M, +16% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $86.7M, +10% on a year earlier; public on 27 Feb 2025
Quarter ended 31 Mar 2025: $74.9M, +96% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $62.2M, +38% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $210.5M, +175% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $172.9M, +99% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $100.8M, +35% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $108.0M, +74% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $180.7M, -14% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 376; public on 14 Feb 2022
31 Mar 2022 report: 400; public on 16 May 2022
30 Jun 2022 report: 440; public on 15 Aug 2022
30 Sep 2022 report: 415; public on 14 Nov 2022
31 Dec 2022 report: 469; public on 14 Feb 2023
31 Mar 2023 report: 464; public on 15 May 2023
30 Jun 2023 report: 433; public on 14 Aug 2023
30 Sep 2023 report: 467; public on 14 Nov 2023
31 Dec 2023 report: 500; public on 14 Feb 2024
31 Mar 2024 report: 491; public on 15 May 2024
30 Jun 2024 report: 531; public on 14 Aug 2024
30 Sep 2024 report: 580; public on 14 Nov 2024
31 Dec 2024 report: 643; public on 14 Feb 2025
31 Mar 2025 report: 634; public on 15 May 2025
30 Jun 2025 report: 634; public on 14 Aug 2025
30 Sep 2025 report: 665; public on 14 Nov 2025
31 Dec 2025 report: 791; public on 17 Feb 2026
31 Mar 2026 report: 828; public on 15 May 2026
30 Jun 2026 report: 858; public on 14 Aug 2026
30 Sep 2026 report: 839; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $24K published
Month from 1 Dec 2021: $393K published
Month from 1 Jan 2022: $97K published
Month from 1 Feb 2022: $83K published
Month from 1 Mar 2022: -$450K published
Month from 1 Apr 2022: $113K published
Month from 1 May 2022: $289K published
Month from 1 Jun 2022: $27K published
Month from 1 Jul 2022: $56K published
Month from 1 Aug 2022: $234K published
Month from 1 Sep 2022: $68K published
Month from 1 Oct 2022: $111K published
Month from 1 Nov 2022: $155K published
Month from 1 Dec 2022: $70K published
Month from 1 Jan 2023: $104K published
Month from 1 Feb 2023: $108K published
Month from 1 Mar 2023: $265K published
Month from 1 Apr 2023: $132K published
Month from 1 May 2023: $420K published
Month from 1 Jun 2023: $60K published
Month from 1 Jul 2023: $90K published
Month from 1 Aug 2023: $120K published
Month from 1 Sep 2023: $104K published
Month from 1 Oct 2023: $393K published
Month from 1 Nov 2023: $44K published
Month from 1 Dec 2023: -$67K published
Month from 1 Jan 2024: $443K published
Month from 1 Feb 2024: $65K published
Month from 1 Mar 2024: $266K published
Month from 1 Apr 2024: $267K published
Month from 1 May 2024: $188K published
Month from 1 Jun 2024: $138K published
Month from 1 Jul 2024: $81K published
Month from 1 Aug 2024: $127K published
Month from 1 Sep 2024: $77K published
Month from 1 Oct 2024: $148K published
Month from 1 Nov 2024: -$2K published
Month from 1 Dec 2024: $32K published
Month from 1 Jan 2025: $47K published
Month from 1 Feb 2025: $49K published
Month from 1 Mar 2025: $61K published
Month from 1 Apr 2025: -$27K published
Month from 1 May 2025: -$56K published
Month from 1 Jun 2025: -$25K published
Month from 1 Jul 2025: $84K published
Month from 1 Aug 2025: $141K published
Month from 1 Sep 2025: $63K published
Month from 1 Oct 2025: $412K published
Month from 1 Nov 2025: $33K published
Month from 1 Dec 2025: $33K published
Month from 1 Jan 2026: $85K published
Month from 1 Feb 2026: $119K published
Month from 1 Mar 2026: $152K published
Month from 1 Apr 2026: -$135K published
Month from 1 May 2026: $169K published
Month from 1 Jun 2026: $185K published
Month from 1 Jul 2026: $113K published
Month from 1 Aug 2026: $17K published
Month from 1 Sep 2026: $15K published
Lobbying spend
Quarter from 1 Oct 2025: $20K published
Quarter from 1 Jan 2026: $60K published
Quarter from 1 Apr 2026: $80K published
Quarter from 1 Jul 2026: $80K published
Quarter from 1 Oct 2026: $80K published

What is unusual now

  • Made public in the last 90 days: it had 3.6M shares sold short in the 30 Sep 2026 report, 1.6× the same report last year.
  • Short interest spike: had 3.6M shares sold short in the 30 Sep 2026 report, 1.6× the same report last year Public on 10 Oct 2026.
  • Insider net buying (open market): Insiders sold a net $1.4B in the last 12 months (the 12 months before: -$422.8M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 15 published in the last 12 months, +50% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 74 sales, $343.3M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Nov 2026Paul A MahonEVP & GENERAL COUNSELSellplanned in advance (10b5-1); after exercising options8,300$565.09$4.7MForm 4
19 Nov 2026Martine A RothblattChairperson & CEOSellplanned in advance (10b5-1); after exercising options5,410$578.83$3.1MForm 4
18 Nov 2026Martine A RothblattChairperson & CEOSellplanned in advance (10b5-1); after exercising options9,500$580.43$5.5MForm 4
17 Nov 2026Martine A RothblattChairperson & CEOSellplanned in advance (10b5-1); after exercising options9,500$587.74$5.6MForm 4
16 Nov 2026Martine A RothblattChairperson & CEOSellplanned in advance (10b5-1); after exercising options9,500$592.42$5.6MForm 4
13 Nov 2026Martine A RothblattChairperson & CEOSellplanned in advance (10b5-1); after exercising options9,500$593.52$5.6MForm 4
12 Nov 2026Martine A RothblattChairperson & CEOSellplanned in advance (10b5-1); after exercising options9,500$593.99$5.6MForm 4
12 Nov 2026Martine A RothblattChairperson & CEOSellplanned in advance (10b5-1); after exercising options9,500$586.32$5.6MForm 4

839 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 73 opened a position, 104 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.5.6M13.1%$3.0B+281K+5.3%
Avoro Capital Advisors LLC2.8M6.47%$1.5B-22K-0.8%
State Street Corp2.0M4.58%$1.1B+54K+2.9%
Vanguard Capital Management LLC1.9M4.53%$1.0B+11K+0.6%
Vanguard Portfolio Management LLC1.9M4.49%$1.0B-7,899-0.4%
Wellington Management Group LLP1.9M4.46%$1.0B+521K+38%
Renaissance Technologies LLC1.7M3.94%$908.2M-33K-1.9%
Amundi989K2.32%$535.8M+770K+351%
Geode Capital Management, LLC975K2.29%$527.2M-22K-2.2%
Citadel Advisors LLC928K2.18%$503.1M+624K+205%

Company events

All 42 company events

In 12 months: 3 director or officer changes, 2 major agreements. Results releases and routine reports are left out.

FiledWhat happenedSource
8 Sep 2026Signed a major agreement8-K
23 Jul 2026Director or officer change8-K
29 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
9 Mar 2026Signed a major agreement8-K
22 Jan 2026Director or officer changeSame filing: changed its bylaws or fiscal year8-K
1 Aug 2025Signed a major agreement8-K
27 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
28 Apr 2025Signed a major agreement; A major agreement endedSame filing: took on new debt8-K

Reported lobbying spend: $80K in Q3 2026, $80K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Sep 2025NewTiber Creek Groupfor United Therapeutics CorporationIssues related to pharmaceuticals and organ transplantation.Health issuesFiling
1 Jan 2010EndedFoley & Lardner LLPfor United TherapeuticsNot statedFiling
26 Sep 2008NewFoley & Lardner LLPfor United TherapeuticsApproval and funding for development and application of broad spectrum antiviral drugsScience/technology, PharmacyFiling

The 5 newest of 391 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

19 Apr 2026confirmed

Confirmed across sources Lobbying and Short interest and volume

United Therapeutics (UTHR): had 2.8M shares sold short in the 13 Mar 2026 report, 1.6× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 18 days.

  • Short interest and volume: Short interest spike, became public on 25 Mar 2026
  • Short interest and volume: Short interest spike, became public on 11 Apr 2026
  • Lobbying: Lobbying on a new issue, became public on 19 Apr 2026
2025-03-14: 1.8M2025-03-31: 1.7M2025-04-15: 1.7M2025-04-30: 2.0M2025-05-15: 2.1M2025-05-30: 1.9M2025-06-13: 1.6M2025-06-30: 1.6M2025-07-15: 1.6M2025-07-31: 1.6M2025-08-15: 2.9M2025-08-29: 2.7M2025-09-15: 2.8M2025-09-30: 2.2M2025-10-15: 2.0M2025-10-31: 1.7M2025-11-14: 1.7M2025-11-28: 1.8M2025-12-15: 2.1M2025-12-31: 1.8M2026-01-15: 1.8M2026-01-30: 1.7M2026-02-13: 1.8M2026-02-27: 1.7M2026-03-13: 2.8M
The 13 Mar 2026 report against the 24 reports before it. this reportearliernormal: 1.8M
See the evidence (3 changes)

Short interest and volume: Short interest spike became public on 25 Mar 2026

United Therapeutics had 2.8M shares sold short in the 13 Mar 2026 report, 1.6× the same report last year.

This period
2.8M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
158K
How far from its usual level
+4.4
Same report last year
1.8M
History used
2,996 days
2025-03-14: 1.8M2025-03-31: 1.7M2025-04-15: 1.7M2025-04-30: 2.0M2025-05-15: 2.1M2025-05-30: 1.9M2025-06-13: 1.6M2025-06-30: 1.6M2025-07-15: 1.6M2025-07-31: 1.6M2025-08-15: 2.9M2025-08-29: 2.7M2025-09-15: 2.8M2025-09-30: 2.2M2025-10-15: 2.0M2025-10-31: 1.7M2025-11-14: 1.7M2025-11-28: 1.8M2025-12-15: 2.1M2025-12-31: 1.8M2026-01-15: 1.8M2026-01-30: 1.7M2026-02-13: 1.8M2026-02-27: 1.7M2026-03-13: 2.8M
the 13 Mar 2026 report24 earlier reportsnormal: 1.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Apr 2026

United Therapeutics had 2.8M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.

This period
2.8M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
176K
How far from its usual level
+4.0
Same report last year
1.7M
History used
3,014 days
2025-03-31: 1.7M2025-04-15: 1.7M2025-04-30: 2.0M2025-05-15: 2.1M2025-05-30: 1.9M2025-06-13: 1.6M2025-06-30: 1.6M2025-07-15: 1.6M2025-07-31: 1.6M2025-08-15: 2.9M2025-08-29: 2.7M2025-09-15: 2.8M2025-09-30: 2.2M2025-10-15: 2.0M2025-10-31: 1.7M2025-11-14: 1.7M2025-11-28: 1.8M2025-12-15: 2.1M2025-12-31: 1.8M2026-01-15: 1.8M2026-01-30: 1.7M2026-02-13: 1.8M2026-02-27: 1.7M2026-03-13: 2.8M2026-03-31: 2.8M
the 31 Mar 2026 report24 earlier reportsnormal: 1.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Lobbying: Lobbying on a new issue became public on 19 Apr 2026

United Therapeutics lobbying on a new issue.

New
['HCR']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4687398

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 10 Oct 2026Short interest and volume change

    had 3.6M shares sold short in the 30 Sep 2026 report, 1.6× the same report last year.

    Same report last year: 2.2M; its normal report is 2.1M.

    See the evidence
    This period
    3.6M (the 30 Sep 2026 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    260K
    How far from its usual level
    +3.9
    Same report last year
    2.2M
    History used
    3,197 days
    2025-09-30: 2.2M2025-10-15: 2.0M2025-10-31: 1.7M2025-11-14: 1.7M2025-11-28: 1.8M2025-12-15: 2.1M2025-12-31: 1.8M2026-01-15: 1.8M2026-01-30: 1.7M2026-02-13: 1.8M2026-02-27: 1.7M2026-03-13: 2.8M2026-03-31: 2.8M2026-04-15: 2.7M2026-04-30: 2.4M2026-05-15: 2.3M2026-05-29: 2.2M2026-06-15: 2.1M2026-06-30: 2.1M2026-07-15: 2.1M2026-07-31: 2.3M2026-08-14: 2.1M2026-08-31: 2.1M2026-09-15: 2.8M2026-09-30: 3.6M
    the 30 Sep 2026 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 23 Jul 2026Filings record

    Director or officer change

  3. 29 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 29 Jun 2026Filings record

    Director or officer change

  5. 28 May 2026Insiders record

    ROTHBLATT MARTINE A (Chairperson & CEO) bought 1,500 shares of UTHR ($863,940) (dated 27 May 2026)

  6. 19 Apr 2026several at once

    had 2.8M shares sold short in the 13 Mar 2026 report, 1.6× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 18 days.

    See the evidence (3 changes)

    Short interest and volume: Short interest spike became public on 25 Mar 2026

    United Therapeutics had 2.8M shares sold short in the 13 Mar 2026 report, 1.6× the same report last year.

    This period
    2.8M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    158K
    How far from its usual level
    +4.4
    Same report last year
    1.8M
    History used
    2,996 days
    2025-03-14: 1.8M2025-03-31: 1.7M2025-04-15: 1.7M2025-04-30: 2.0M2025-05-15: 2.1M2025-05-30: 1.9M2025-06-13: 1.6M2025-06-30: 1.6M2025-07-15: 1.6M2025-07-31: 1.6M2025-08-15: 2.9M2025-08-29: 2.7M2025-09-15: 2.8M2025-09-30: 2.2M2025-10-15: 2.0M2025-10-31: 1.7M2025-11-14: 1.7M2025-11-28: 1.8M2025-12-15: 2.1M2025-12-31: 1.8M2026-01-15: 1.8M2026-01-30: 1.7M2026-02-13: 1.8M2026-02-27: 1.7M2026-03-13: 2.8M
    the 13 Mar 2026 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Apr 2026

    United Therapeutics had 2.8M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.

    This period
    2.8M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    176K
    How far from its usual level
    +4.0
    Same report last year
    1.7M
    History used
    3,014 days
    2025-03-31: 1.7M2025-04-15: 1.7M2025-04-30: 2.0M2025-05-15: 2.1M2025-05-30: 1.9M2025-06-13: 1.6M2025-06-30: 1.6M2025-07-15: 1.6M2025-07-31: 1.6M2025-08-15: 2.9M2025-08-29: 2.7M2025-09-15: 2.8M2025-09-30: 2.2M2025-10-15: 2.0M2025-10-31: 1.7M2025-11-14: 1.7M2025-11-28: 1.8M2025-12-15: 2.1M2025-12-31: 1.8M2026-01-15: 1.8M2026-01-30: 1.7M2026-02-13: 1.8M2026-02-27: 1.7M2026-03-13: 2.8M2026-03-31: 2.8M
    the 31 Mar 2026 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Lobbying: Lobbying on a new issue became public on 19 Apr 2026

    United Therapeutics lobbying on a new issue.

    New
    ['HCR']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4687398

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  7. 19 Apr 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['HCR']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4687398
  8. 11 Apr 2026Short interest and volume change

    had 2.8M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.

    Same report last year: 1.7M; its normal report is 1.8M.

    See the evidence
    This period
    2.8M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    176K
    How far from its usual level
    +4.0
    Same report last year
    1.7M
    History used
    3,014 days
    2025-03-31: 1.7M2025-04-15: 1.7M2025-04-30: 2.0M2025-05-15: 2.1M2025-05-30: 1.9M2025-06-13: 1.6M2025-06-30: 1.6M2025-07-15: 1.6M2025-07-31: 1.6M2025-08-15: 2.9M2025-08-29: 2.7M2025-09-15: 2.8M2025-09-30: 2.2M2025-10-15: 2.0M2025-10-31: 1.7M2025-11-14: 1.7M2025-11-28: 1.8M2025-12-15: 2.1M2025-12-31: 1.8M2026-01-15: 1.8M2026-01-30: 1.7M2026-02-13: 1.8M2026-02-27: 1.7M2026-03-13: 2.8M2026-03-31: 2.8M
    the 31 Mar 2026 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 25 Mar 2026Short interest and volume change

    had 2.8M shares sold short in the 13 Mar 2026 report, 1.6× the same report last year.

    Same report last year: 1.8M; its normal report is 1.8M.

    See the evidence
    This period
    2.8M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    158K
    How far from its usual level
    +4.4
    Same report last year
    1.8M
    History used
    2,996 days
    2025-03-14: 1.8M2025-03-31: 1.7M2025-04-15: 1.7M2025-04-30: 2.0M2025-05-15: 2.1M2025-05-30: 1.9M2025-06-13: 1.6M2025-06-30: 1.6M2025-07-15: 1.6M2025-07-31: 1.6M2025-08-15: 2.9M2025-08-29: 2.7M2025-09-15: 2.8M2025-09-30: 2.2M2025-10-15: 2.0M2025-10-31: 1.7M2025-11-14: 1.7M2025-11-28: 1.8M2025-12-15: 2.1M2025-12-31: 1.8M2026-01-15: 1.8M2026-01-30: 1.7M2026-02-13: 1.8M2026-02-27: 1.7M2026-03-13: 2.8M
    the 13 Mar 2026 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 26 Feb 2026Financials change

    spent $172.9M on capital projects in the quarter ended 31 Dec 2025, 2.0× the same quarter last year.

    Same quarter last year: $86.7M; its normal quarter is $75.7M.

    See the evidence
    This period
    $172.9M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $75.7M
    Typical spread (median absolute deviation)
    $12.2M
    How far from its usual level
    +5.4
    Same quarter last year
    $86.7M
    History used
    3,562 days
    2023-12-31: $78.7M2024-03-31: $38.2M2024-06-30: $45.1M2024-09-30: $76.5M2024-12-31: $86.7M2025-03-31: $74.9M2025-06-30: $62.2M2025-09-30: $210.5M2025-12-31: $172.9M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $75.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  11. 22 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 22 Jan 2026Filings record

    Director or officer change

  13. 18 Jan 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['POS']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4689614
  14. 30 Oct 2025Financials change

    spent $210.5M on capital projects in the quarter ended 30 Sep 2025, 2.8× the same quarter last year.

    Same quarter last year: $76.5M; its normal quarter is $70.3M.

    See the evidence
    This period
    $210.5M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $70.3M
    Typical spread (median absolute deviation)
    $8.2M
    How far from its usual level
    +11.5
    Same quarter last year
    $76.5M
    History used
    3,470 days
    2023-09-30: $65.7M2023-12-31: $78.7M2024-03-31: $38.2M2024-06-30: $45.1M2024-09-30: $76.5M2024-12-31: $86.7M2025-03-31: $74.9M2025-06-30: $62.2M2025-09-30: $210.5M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $70.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  15. 16 Oct 2025Lobbying record

    UNITED THERAPEUTICS CORPORATION: new lobbying registration (TIBER CREEK GROUP) (dated 1 Sep 2025)

  16. 27 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 27 Jun 2025Filings record

    Director or officer change

  18. 28 Apr 2025Filings record

    A major agreement ended

  19. 12 Sep 2024Short interest and volume change

    had 4.1M shares sold short in the 30 Aug 2024 report, 3.7× the same report last year.

    Same report last year: 1.1M; its normal report is 1.2M.

    See the evidence
    This period
    4.1M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    243K
    How far from its usual level
    +7.9
    Same report last year
    1.1M
    History used
    2,436 days
    2023-08-31: 1.1M2023-09-15: 1.1M2023-09-29: 962K2023-10-13: 1.0M2023-10-31: 1.1M2023-11-15: 1.1M2023-11-30: 1.1M2023-12-15: 1.3M2023-12-29: 1.1M2024-01-12: 1.2M2024-01-31: 1.0M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 1.9M2024-03-28: 4.9M2024-04-15: 4.3M2024-04-30: 3.9M2024-05-15: 3.8M2024-05-31: 3.9M2024-06-14: 4.4M2024-06-28: 4.4M2024-07-15: 4.2M2024-07-31: 4.1M2024-08-15: 4.1M2024-08-30: 4.1M
    the 30 Aug 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 27 Aug 2024Short interest and volume change

    had 4.1M shares sold short in the 15 Aug 2024 report, 2.2× the same report last year.

    Same report last year: 1.9M; its normal report is 1.2M.

    See the evidence
    This period
    4.1M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    243K
    How far from its usual level
    +8.1
    Same report last year
    1.9M
    History used
    2,421 days
    2023-08-15: 1.9M2023-08-31: 1.1M2023-09-15: 1.1M2023-09-29: 962K2023-10-13: 1.0M2023-10-31: 1.1M2023-11-15: 1.1M2023-11-30: 1.1M2023-12-15: 1.3M2023-12-29: 1.1M2024-01-12: 1.2M2024-01-31: 1.0M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 1.9M2024-03-28: 4.9M2024-04-15: 4.3M2024-04-30: 3.9M2024-05-15: 3.8M2024-05-31: 3.9M2024-06-14: 4.4M2024-06-28: 4.4M2024-07-15: 4.2M2024-07-31: 4.1M2024-08-15: 4.1M
    the 15 Aug 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 10 Aug 2024Short interest and volume change

    had 4.1M shares sold short in the 31 Jul 2024 report, 4.2× the same report last year.

    Same report last year: 971K; its normal report is 1.2M.

    See the evidence
    This period
    4.1M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    174K
    How far from its usual level
    +11.4
    Same report last year
    971K
    History used
    2,406 days
    2023-07-31: 971K2023-08-15: 1.9M2023-08-31: 1.1M2023-09-15: 1.1M2023-09-29: 962K2023-10-13: 1.0M2023-10-31: 1.1M2023-11-15: 1.1M2023-11-30: 1.1M2023-12-15: 1.3M2023-12-29: 1.1M2024-01-12: 1.2M2024-01-31: 1.0M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 1.9M2024-03-28: 4.9M2024-04-15: 4.3M2024-04-30: 3.9M2024-05-15: 3.8M2024-05-31: 3.9M2024-06-14: 4.4M2024-06-28: 4.4M2024-07-15: 4.2M2024-07-31: 4.1M
    the 31 Jul 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 25 Jul 2024Short interest and volume change

    had 4.2M shares sold short in the 15 Jul 2024 report, 4.2× the same report last year.

    Same report last year: 993K; its normal report is 1.2M.

    See the evidence
    This period
    4.2M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    152K
    How far from its usual level
    +13.3
    Same report last year
    993K
    History used
    2,390 days
    2023-07-14: 993K2023-07-31: 971K2023-08-15: 1.9M2023-08-31: 1.1M2023-09-15: 1.1M2023-09-29: 962K2023-10-13: 1.0M2023-10-31: 1.1M2023-11-15: 1.1M2023-11-30: 1.1M2023-12-15: 1.3M2023-12-29: 1.1M2024-01-12: 1.2M2024-01-31: 1.0M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 1.9M2024-03-28: 4.9M2024-04-15: 4.3M2024-04-30: 3.9M2024-05-15: 3.8M2024-05-31: 3.9M2024-06-14: 4.4M2024-06-28: 4.4M2024-07-15: 4.2M
    the 15 Jul 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 11 Jul 2024Short interest and volume change

    had 4.4M shares sold short in the 28 Jun 2024 report, 4.1× the same report last year.

    Same report last year: 1.1M; its normal report is 1.1M.

    See the evidence
    This period
    4.4M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    134K
    How far from its usual level
    +16.4
    Same report last year
    1.1M
    History used
    2,373 days
    2023-06-30: 1.1M2023-07-14: 993K2023-07-31: 971K2023-08-15: 1.9M2023-08-31: 1.1M2023-09-15: 1.1M2023-09-29: 962K2023-10-13: 1.0M2023-10-31: 1.1M2023-11-15: 1.1M2023-11-30: 1.1M2023-12-15: 1.3M2023-12-29: 1.1M2024-01-12: 1.2M2024-01-31: 1.0M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 1.9M2024-03-28: 4.9M2024-04-15: 4.3M2024-04-30: 3.9M2024-05-15: 3.8M2024-05-31: 3.9M2024-06-14: 4.4M2024-06-28: 4.4M
    the 28 Jun 2024 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 27 Jun 2024Short interest and volume change

    had 4.4M shares sold short in the 14 Jun 2024 report, 3.8× the same report last year.

    Same report last year: 1.1M; its normal report is 1.1M.

    See the evidence
    This period
    4.4M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    106K
    How far from its usual level
    +20.5
    Same report last year
    1.1M
    History used
    2,359 days
    2023-06-15: 1.1M2023-06-30: 1.1M2023-07-14: 993K2023-07-31: 971K2023-08-15: 1.9M2023-08-31: 1.1M2023-09-15: 1.1M2023-09-29: 962K2023-10-13: 1.0M2023-10-31: 1.1M2023-11-15: 1.1M2023-11-30: 1.1M2023-12-15: 1.3M2023-12-29: 1.1M2024-01-12: 1.2M2024-01-31: 1.0M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 1.9M2024-03-28: 4.9M2024-04-15: 4.3M2024-04-30: 3.9M2024-05-15: 3.8M2024-05-31: 3.9M2024-06-14: 4.4M
    the 14 Jun 2024 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 27 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 27 Jun 2024Filings record

    Director or officer change

  27. 12 Jun 2024Short interest and volume change

    had 3.9M shares sold short in the 31 May 2024 report, 3.7× the same report last year.

    Same report last year: 1.0M; its normal report is 1.1M.

    See the evidence
    This period
    3.9M (the 31 May 2024 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    98K
    How far from its usual level
    +18.9
    Same report last year
    1.0M
    History used
    2,345 days
    2023-05-31: 1.0M2023-06-15: 1.1M2023-06-30: 1.1M2023-07-14: 993K2023-07-31: 971K2023-08-15: 1.9M2023-08-31: 1.1M2023-09-15: 1.1M2023-09-29: 962K2023-10-13: 1.0M2023-10-31: 1.1M2023-11-15: 1.1M2023-11-30: 1.1M2023-12-15: 1.3M2023-12-29: 1.1M2024-01-12: 1.2M2024-01-31: 1.0M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 1.9M2024-03-28: 4.9M2024-04-15: 4.3M2024-04-30: 3.9M2024-05-15: 3.8M2024-05-31: 3.9M
    the 31 May 2024 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 25 May 2024Short interest and volume change

    had 3.8M shares sold short in the 15 May 2024 report, 2.8× the same report last year.

    Same report last year: 1.3M; its normal report is 1.1M.

    See the evidence
    This period
    3.8M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    98K
    How far from its usual level
    +18.1
    Same report last year
    1.3M
    History used
    2,329 days
    2023-05-15: 1.3M2023-05-31: 1.0M2023-06-15: 1.1M2023-06-30: 1.1M2023-07-14: 993K2023-07-31: 971K2023-08-15: 1.9M2023-08-31: 1.1M2023-09-15: 1.1M2023-09-29: 962K2023-10-13: 1.0M2023-10-31: 1.1M2023-11-15: 1.1M2023-11-30: 1.1M2023-12-15: 1.3M2023-12-29: 1.1M2024-01-12: 1.2M2024-01-31: 1.0M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 1.9M2024-03-28: 4.9M2024-04-15: 4.3M2024-04-30: 3.9M2024-05-15: 3.8M
    the 15 May 2024 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 10 May 2024Short interest and volume change

    had 3.9M shares sold short in the 30 Apr 2024 report, 2.6× the same report last year.

    Same report last year: 1.5M; its normal report is 1.1M.

    See the evidence
    This period
    3.9M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    98K
    How far from its usual level
    +18.7
    Same report last year
    1.5M
    History used
    2,314 days
    2023-04-28: 1.5M2023-05-15: 1.3M2023-05-31: 1.0M2023-06-15: 1.1M2023-06-30: 1.1M2023-07-14: 993K2023-07-31: 971K2023-08-15: 1.9M2023-08-31: 1.1M2023-09-15: 1.1M2023-09-29: 962K2023-10-13: 1.0M2023-10-31: 1.1M2023-11-15: 1.1M2023-11-30: 1.1M2023-12-15: 1.3M2023-12-29: 1.1M2024-01-12: 1.2M2024-01-31: 1.0M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 1.9M2024-03-28: 4.9M2024-04-15: 4.3M2024-04-30: 3.9M
    the 30 Apr 2024 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 25 Apr 2024Short interest and volume change

    had 4.3M shares sold short in the 15 Apr 2024 report, 3.1× the same report last year.

    Same report last year: 1.4M; its normal report is 1.1M.

    See the evidence
    This period
    4.3M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    98K
    How far from its usual level
    +21.9
    Same report last year
    1.4M
    History used
    2,299 days
    2023-04-14: 1.4M2023-04-28: 1.5M2023-05-15: 1.3M2023-05-31: 1.0M2023-06-15: 1.1M2023-06-30: 1.1M2023-07-14: 993K2023-07-31: 971K2023-08-15: 1.9M2023-08-31: 1.1M2023-09-15: 1.1M2023-09-29: 962K2023-10-13: 1.0M2023-10-31: 1.1M2023-11-15: 1.1M2023-11-30: 1.1M2023-12-15: 1.3M2023-12-29: 1.1M2024-01-12: 1.2M2024-01-31: 1.0M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 1.9M2024-03-28: 4.9M2024-04-15: 4.3M
    the 15 Apr 2024 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 10 Apr 2024Short interest and volume change

    had 4.9M shares sold short in the 28 Mar 2024 report, 3.4× the same report last year.

    Same report last year: 1.4M; its normal report is 1.1M.

    See the evidence
    This period
    4.9M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    98K
    How far from its usual level
    +25.8
    Same report last year
    1.4M
    History used
    2,281 days
    2023-03-31: 1.4M2023-04-14: 1.4M2023-04-28: 1.5M2023-05-15: 1.3M2023-05-31: 1.0M2023-06-15: 1.1M2023-06-30: 1.1M2023-07-14: 993K2023-07-31: 971K2023-08-15: 1.9M2023-08-31: 1.1M2023-09-15: 1.1M2023-09-29: 962K2023-10-13: 1.0M2023-10-31: 1.1M2023-11-15: 1.1M2023-11-30: 1.1M2023-12-15: 1.3M2023-12-29: 1.1M2024-01-12: 1.2M2024-01-31: 1.0M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 1.9M2024-03-28: 4.9M
    the 28 Mar 2024 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 27 Mar 2024Short interest and volume change

    had 1.9M shares sold short in the 15 Mar 2024 report, 1.4× the same report last year.

    Same report last year: 1.3M; its normal report is 1.1M.

    See the evidence
    This period
    1.9M (the 15 Mar 2024 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    98K
    How far from its usual level
    +5.4
    Same report last year
    1.3M
    History used
    2,268 days
    2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.4M2023-04-28: 1.5M2023-05-15: 1.3M2023-05-31: 1.0M2023-06-15: 1.1M2023-06-30: 1.1M2023-07-14: 993K2023-07-31: 971K2023-08-15: 1.9M2023-08-31: 1.1M2023-09-15: 1.1M2023-09-29: 962K2023-10-13: 1.0M2023-10-31: 1.1M2023-11-15: 1.1M2023-11-30: 1.1M2023-12-15: 1.3M2023-12-29: 1.1M2024-01-12: 1.2M2024-01-31: 1.0M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 1.9M
    the 15 Mar 2024 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 25 Aug 2023Short interest and volume change

    had 1.9M shares sold short in the 15 Aug 2023 report, 1.8× the same report last year.

    Same report last year: 1.1M; its normal report is 1.3M.

    See the evidence
    This period
    1.9M (the 15 Aug 2023 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    85K
    How far from its usual level
    +4.2
    Same report last year
    1.1M
    History used
    2,055 days
    2022-08-15: 1.1M2022-08-31: 877K2022-09-15: 1.2M2022-09-30: 1.3M2022-10-14: 1.4M2022-10-31: 1.3M2022-11-15: 1.4M2022-11-30: 1.3M2022-12-15: 1.1M2022-12-30: 1.3M2023-01-13: 1.3M2023-01-31: 1.3M2023-02-15: 1.4M2023-02-28: 1.3M2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.4M2023-04-28: 1.5M2023-05-15: 1.3M2023-05-31: 1.0M2023-06-15: 1.1M2023-06-30: 1.1M2023-07-14: 993K2023-07-31: 971K2023-08-15: 1.9M
    the 15 Aug 2023 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 28 Jun 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 28 Jun 2023Filings record

    Director or officer change

  36. 4 May 2023Insiders record

    PATUSKY CHRISTOPHER (director) bought 21 shares of UTHR ($2,422) (dated 3 May 2023)

  37. 8 Nov 2022Financials change

    spent $68.8M on capital projects in the quarter ended 30 Sep 2022, 3.0× the same quarter last year.

    Same quarter last year: $23.3M; its normal quarter is $16.1M.

    See the evidence
    This period
    $68.8M (the quarter ended 30 Sep 2022)
    Normal quarter (median of 8 earlier)
    $16.1M
    Typical spread (median absolute deviation)
    $3.1M
    How far from its usual level
    +11.3
    Same quarter last year
    $23.3M
    History used
    4,748 days
    2020-09-30: $15.8M2020-12-31: $12.3M2021-03-31: $10.6M2021-06-30: $16.3M2021-09-30: $23.3M2021-12-31: $70.6M2022-03-31: $13.5M2022-06-30: $17.0M2022-09-30: $68.8M
    the quarter ended 30 Sep 20228 earlier quartersnormal: $16.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  38. 28 Jun 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 28 Jun 2022Filings record

    Director or officer change

  40. 1 Apr 2022Filings record

    A major agreement ended

Showing the newest 40 of 63 entries; narrow the window or the kind of data to see older ones.

Not listed: 1020 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001082554
Ticker
UTHR
Domain
unither.com
Employer name
UNITED THERAPEUTICS (1 unverified)
Hq location
MD|SILVER SPRING|20910 (1 unverified)
Lobbying client
united therapeutics
Name
1109 Spring Managing Holdings, LLC, a Delaware limited liability company, 1109 Spring Managing Member, LLC, a Delaware limited liability company, 1111 Spring Holdings, LLC, a Delaware limited liability company, Document and 18 more
Uei
KK5FBFA43JS7
Wikipedia
United Therapeutics
  • DOL H-1B labor condition applications and PERM certifications250 data points14 Oct 2019 to 21 Sep 2026
  • Federal lobbying disclosures (LDA)3 records, 36 data points26 Sep 2008 to 30 Sep 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)185 records19 Jan 2016 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1230 data points31 Dec 2007 to 28 Oct 2026
  • SEC Form 4 insider transactions859 records, 2728 data points7 Jan 2016 to 19 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards2832 data points14 Nov 2007 to 18 Sep 2026
  • Wikipedia pageviews10 data points11 Nov 2026 to 20 Nov 2026